PCSK9 inhibitors × cardiovascular events

TrialThe lancet. Diabetes & endocrinology2017

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.

Marc S Sabatine et al.PubMed ↗Publisher ↗

What the trial testedrandomised · 564 people · 2017

Randomised comparison

Probably reduced cardiovascular events

−17%−25% to −7%

Bigger than 4 in 10 for cardiovascular events

As reported

HR 0.83, 95% CI 0.75–0.93

One number in the abstract

the abstract, start to end

endpoint, the hazard ratios (HRs) were 0.83 (95% CI 0.75-0.93; p=0.0008)

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
HR 0.830.75–0.93
PCSK9 inhibitorsCardiovascular events

PCSK9 inhibitors × cardiovascular eventshelps?settled

unlikelylikely
1.001.00 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

250 papers cite itlatest 60 shown

2017
2019
2020
2021
2022
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 28927706